No Data
No Data
H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $18
Express News | HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
Positive Outlook for Tenaya Therapeutics: Strong Potential in Gene Therapy for Cardiovascular Diseases Supports Buy Rating
Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Express News | Tenaya Therapeutics Inc - Initial Clinical Data for Ridge-1 Expected in 2025
Express News | Tenaya Therapeutics Doses First Patient in Ridge™-1 Phase 1B Clinical Trial of Tn-401 for the Treatment of Pkp2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
No Data
No Data
amiable Llama_6295 : At last moving up